66 results about "Anticoagulant Agent" patented technology

Provided herein are methods and compositions for treating a coagulopathy in a subject. Such methods can include administering to the subject in need thereof, for example because they have been administered an anticoagulant agent, an effective amount of a composition including platelets, or in illustrative embodiments platelet derivatives, and in further illustrative embodiments freeze-dried platelet derivatives (FDPDs). Various properties of exemplary embodiments of such methods and platelet derivatives used therein, as well as numerous additional aspects and embodiments are provided herein.

A class of proteins that inhibit thrombin, particularly direct inhibitor of thrombin modified from sculptin, identified in the transcriptomics analysis of the salivary glands of ticks, as well as fragments and recombinant protein thereof, which can be used as anticoagulant agents and for the prophylaxis and / or treatment of thromboembolic diseases. These proteins fall within the fields of biochemistry, molecular biology, genetics, pharmacy and medicinal chemistry, being related to biochemical and metabolic processes.

The invention discloses a blood detection device and a detection method thereof, and belongs to the technical field of medical instruments. A blood detection device comprises a workbench and further comprises a detection disc with a cavity, the detection disc is fixedly connected to the workbench, a shaking mixing mechanism is arranged in the cavity of the detection disc, and a containing hole is formed in the top of the detection disc; the device can continuously and softly shake an anticoagulant and blood in the blood collection tube, so that the phenomenon of blood coagulation caused by non-uniform mixing is avoided, medical staff can quickly and uniformly mix and softly shake the blood collection tube after blood collection, the phenomenon that the anticoagulant is not fully mixed is prevented, the local concentration uniformity is ensured, and the blood collection tube is prevented from being damaged. The blood collection tube can be shaken within several minutes after blood drawing, it is ensured that an anticoagulant can play a role in time, in this way, the follow-up waiting time of a patient can be shortened, and the workload of medical staff can be reduced.

Provided herein are methods and compositions for treating a coagulopathy in a subject. Such methods can include administering to the subject in need thereof, for example because they have been administered an anticoagulant agent, an effective amount of a composition including platelets, or in illustrative embodiments platelet derivatives, and in further illustrative embodiments freeze-dried platelet derivatives (FDPDs). Various properties of exemplary embodiments of such methods and platelet derivatives used therein, as well as numerous additional aspects and embodiments are provided herein.

Provided herein are methods and compositions for treating a coagulopathy in a subject. Such methods can include administering to the subject in need thereof, for example because they have been administered an anticoagulant agent, an effective amount of a composition including platelets, or in illustrative embodiments platelet derivatives, and in further illustrative embodiments freeze-dried platelet derivatives (FDPDs). Various properties of exemplary embodiments of such methods and platelet derivatives used therein, as well as numerous additional aspects and embodiments are provided herein.

The invention belongs to the technical field of biomedical materials, and particularly relates to a poly-4-methyl-1-pentene (PMP) gas-blood exchange membrane for an extracorporeal membrane oxygenation (ECMO) system, which realizes a long-acting antithrombotic function through a bionic interface construction technology. The invention aims to provide a bionic antithrombotic PMP gas-blood exchange membrane based on zwitter-ion gradient grafting, and through material and process innovation, the following problems existing in a traditional ECMO gas-blood exchange membrane: an antithrombotic coating is easy to fall off, and the long-term effect is insufficient; the risk of blood injury caused by dependence on heparin or anticoagulants; and the surface modification process destroys the membrane pore structure and air permeability.

Provided herein are compositions comprising platelet derivatives, and methods for administering the same to a subject in need thereof. Also provided herein are methods and compositions for reducing bleeding in a subject. Such methods can include administering to the subject in need thereof, for example because they have been or are being treated with an anticoagulant agent, for example, a factor XI inhibitor, and / or an antiplatelet, a dose of rehydrated platelet derivative composition comprising platelet derivatives. Various properties of exemplary embodiments of such methods and platelet derivatives used therein, as well as numerous additional aspects and embodiments are provided herein.

The invention discloses a preparation method of an anticoagulant blood contact material, which comprises the following steps: S1, dissolving a silane reagent containing different functional groups by using ethanol, immersing the blood contact material into the silane solution, and reacting for a period of time in a constant-temperature environment in a dark place for later use; s2, immersing the sample obtained in the step S1 in an ethanol solution containing 1mM of TCEP (tris (2-carboxyethyl) phosphine), reacting, fully cleaning, and carrying out vacuum drying for later use; s3, dissolving an anticoagulant with a PBS (Phosphate Buffer Solution) to obtain an anticoagulant solution for later use; and S4, immersing the sample obtained in the step S2 in the anticoagulant solution prepared in the step S3, fully reacting at a constant temperature, cleaning, and drying with nitrogen to obtain the anticoagulant blood contact material. The method is simple to operate, mild in reaction condition, green, economical, free of large equipment and convenient to popularize and use. The silane reagent is used for treating the blood contact material, so that active groups such as sulfydryl, carboxyl, amido and hydroxyl can be generated on the surface of the material in situ, and meanwhile, the hydrophilicity of the material is improved. Then, the functionalized material is immersed in an anticoagulant solution, an anticoagulant drug is fixed on the surface of the material through a mild click chemical reaction, an amidation reaction and the like, and the blood contact material is endowed with excellent anticoagulant performance.

The utility model provides a blood collection tube convenient to classify, belongs to the technical field of medical instruments, and aims to solve the problem that the mixing efficiency of blood and an anticoagulant is affected due to the fact that the flow range of the blood and the anticoagulant in the blood collection tube is small when the blood in the conventional blood collection tube is over-full. Comprising a first blood collection tube body, a second blood collection tube body, a blood collection tube cap, a blood collection connecting hole, a sealing plug, a blood collection auxiliary mechanism and a classification mixing mechanism, the second blood collection tube body is in interference fit with the lower end of the first blood collection tube body; the blood collection tube cap is inserted into the upper end of the first blood collection tube body, and an anti-skid pattern structure is arranged on the periphery of the blood collection tube cap; the blood collection connecting hole is formed in the middle of the upper end of the blood collection tube cap; the sealing plug is fixedly connected to the upper end in the blood collection tube cap; the blood sampling auxiliary mechanism is arranged on the outer side of the second blood sampling tube body; the classifying and mixing mechanism is arranged in the blood collection tube cap, so that the mixing of the anticoagulant and the blood is accelerated, and the mixing efficiency of the anticoagulant and the blood is improved.

To provide a medicine liquid supply device that is hard to be limited to a packaging material of medicine liquid such as heparin and can be used for multiple treatments by a packaging unit of medicine liquid.SOLUTION: A medicine liquid supply device supplies medicine liquid to a blood circuit included in a blood purification device that purifies blood. The medicine liquid supply device includes: a composition holding part to which an anticoagulant stored in a container can be introduced from the container and that holds a composition containing at least the introduced anticoagulant; and a connection part that connects the composition holding part to the blood circuit and enables the composition to be guided out to the blood circuit from the composition holding part.SELECTED DRAWING: Figure 1

The invention provides a hypertension blood sample protective agent, a vacuum blood collection tube for hypertension blood sample detection and application, and belongs to the technical field of medical instruments, the hypertension blood sample protective agent is characterized by being prepared from the following raw materials in parts by weight: enapremarate, an anticoagulant and a complexing agent; the vacuum blood collection tube for hypertension blood sample detection contains the hypertension blood sample protective agent. According to the application, the vacuum blood collection tube for hypertension blood sample detection is adopted for directly storing blood. By adopting the vacuum blood collection tube for hypertension blood sample detection, the tedious steps of reagent preparation and on-site reagent addition can be reduced, so that the detection efficiency and the accuracy of a detection result are improved.

The utility model discloses a blood filtering treatment device, which relates to the technical field of filtering equipment and comprises a shell, and a liquid outlet notch communicated with an inner cavity of the shell is formed in the bottom wall of the shell; the filter cartridge is fixedly arranged in the cavity of the shell, and a plurality of filtrate ports are formed in the outer wall of the lower part of the filter cartridge in a penetrating manner; the hopper is arranged on the outer wall above the shell, and the lower end of the hopper is communicated with the inner wall of the filter drum. According to the blood filtering treatment device, blood and impurities are separated at a time, meanwhile, the shape of the impurities is not damaged, the product quality is not affected, blood clots coagulated in the blood can be reduced to be in a liquid state through equipment, the cost of an anticoagulant agent is saved from the source, the additional value of the product is greatly improved, and the production cost is reduced. According to the innovation of the equipment, the use area of a filtering workshop is greatly saved, the capital investment is reduced, and the equipment realizes breakthrough innovation in the blood filtering field, integrates independent crushing and independent filtering forms, and realizes the effect of integrating hair removal and pulping.

The invention relates to the technical field of liquid-based cytology, and particularly discloses serosa effusion cell preserving fluid. Comprising a preservation solution, an anticoagulant, a red blood cell treatment solution, a cell membrane stabilizer, an antioxidant and a metal ion chelating agent, the preservation solution contains a buffer system, an energy supply component, an antibiotic and a surfactant, and the red blood cell treatment solution contains a hemolysis active component and a cell immobilization component; the preparation method comprises the following steps: firstly, preparing the preserving fluid, adjusting the pH value, adding the active substances, mixing the antibiotics, and then completing constant volume and sterile filtration; the anticoagulant solution and the red blood cell treating fluid are independently prepared, and sterilization is achieved through filtration; and finally, packaging all the components in a sterilized storage bottle in a matched manner. The composition provided by the invention can be used for preserving cells in a clinical serosal effusion sample, and can provide a high-quality sample for subsequent cell morphology observation or detection; in addition, according to the preparation method, the controllability is high when all the components are independently prepared, and the preserving fluid with the consistent performance can be stably prepared.

The invention relates to the technical field of animal experiment devices, and discloses a mouse blood coagulation preventing device which comprises a plurality of mouse fixing recognition and blood sampling devices, a mouse blood typing instrument, a vortex system, a blood waste liquid collecting device, an anticoagulant premixing system, a micro pump, a plurality of optical sensors and a blood refrigerating box. The mouse fixing recognition and blood sampling device is connected with the mouse blood typing instrument through a pipeline, the mouse blood typing instrument is connected with the vortex system and the blood waste liquid collecting device through pipelines, and the vortex system is connected with the micro pump and the optical sensor through pipelines. The micro pump is connected with the anticoagulant premixing system through a pipeline, and the optical sensor is connected with the blood refrigerating box through a pipeline; the device is high in efficiency, manual operation can be avoided, mechanical damage, pollution in the experiment process and animal stress are reduced, and the possibility of blood coagulation is reduced.

This invention discloses a method and application for fetal red blood cell flow cytometry detection, comprising the following steps: taking fetal blood and placing it in a test tube; adding the test tube containing fetal blood to an anticoagulant tube; adding an anticoagulant to the blood in the anticoagulant tube; placing the anticoagulant tube containing blood and anticoagulant into a blood centrifuge; centrifuging the fetal blood in the anticoagulant tube; after centrifugation, the fetal blood in the anticoagulant tube separates into layers; recording the proportion of each layer; red blood cells are generally in the lowest layer. This invention has the advantage of being able to detect the number of hemoglobin cells in red blood cells, solving the problem that current methods for detecting fetal red blood cells generally only detect the number of fetal red blood cells, and only determine the health of the fetus by the number of fetal red blood cells. The inability to detect the number of hemoglobin cells in fetal red blood cells reduces the accuracy of the detection and is not conducive to understanding the health status of the fetus.

The application belongs to the technical field of biological medicine, and relates to an anticoagulant and application thereof in white blood cell classification for high-precision animal blood cell analyzers. The anticoagulant comprises two parts of buffer and anticoagulant matrix components and active components. In the anticoagulant, the buffer and anticoagulant matrix component formula comprises 1.5-2 g of citrate, 0.3-0.5 g of citric acid and 0.15-0.20 g of EDTA-K2 per 100 mL of the anticoagulant, and the active component comprises 0.08-0.10 g of low-molecular enzymatic hydrolysis carboxymethyl chitosan, 1.0-1.2 g of hydroxypropyl-beta-cyclodextrin, 10-15 mg of dipyridamole and 8-10 mg of aspirin. The anticoagulant effectively inhibits platelet activation, prevents platelet aggregation and white blood cell morphological deformation, accurately identifies in white blood cell five classification, and has a classification accuracy as high as 98%, and is suitable for veterinary clinical hematology examination and animal disease monitoring.

The application discloses a kind of whole-process intelligent quality control and traceability system and method of test specimen, it is related to specimen testing technical field, the application first records the collection information of specimen, then according to the collection information of specimen analysis obtains the configuration information of specimen anticoagulant, and then according to the configuration information corresponding anticoagulant is configured and is added specimen, to obtain the test information of specimen, after testing is completed, the traceability reference value of specimen is analyzed, and the traceability correlation chain is constructed, then determine traceability data, and traceability data is distributed to each traceability node, finally each traceability data and traceability node are stored.The application realizes the individualization intelligent adaptation of anticoagulant proportioning, effectively avoids the test result deviation problem caused by traditional fixed anticoagulant proportioning, simultaneously solves the problem that existing traceability data is scattered and correlation is poor, improves the credibility of traceability data.

A medical device may be coated with a therapeutic composition comprising a direct oral anticoagulant. An exemplary drug coating composition may include an excipient including polylactic acid (PLA), poly (lactic acid-co-glycolic acid) (PLGA), or poly (vinylidene fluoride-co-hexafluoropropylene (PVDF-HFP), and a direct oral anticoagulant (DOAC). An exemplary pharmaceutical coating may be applied to an exterior surface of a medical device.

This invention relates to the field of biomedicine, specifically to the application of banana fruit extract in the preparation of anticoagulant or antithrombotic drugs. The banana fruit extract provided by this invention contains flavonoids, polyphenols, polysaccharides, hydroxyanthraquinones, triterpenoids, and other components. Flavonoids and polyphenols have been widely proven to have anti-inflammatory and antioxidant effects, which can synergistically enhance the anticoagulant effect. The high potassium content of banana fruit can indirectly improve vascular function by regulating sodium-potassium balance. The banana fruit extract provided by this invention can inhibit platelet production or promote platelet metabolism, prolong clotting time, and inhibit platelet aggregation. Its natural plant components interfere with platelet aggregation by inhibiting the production of thromboxane A2, achieving anticoagulant and antithrombotic effects. The mechanism of action of banana fruit extract differs from traditional anticoagulants such as heparin, reducing the risk of bleeding. Its natural component characteristics provide a direction for the development of novel plant-derived anticoagulant drugs.

A method of producing serum or plasma comprises the steps of drawing a blood sample from a subject; adding erythrocyte sedimentation-accelerating agent(s) and an anticoagulant to the blood sample; placing the mixture in a vessel with an inclined well and allowing the phase separation of the solution into an erythrocyte phase and a plasma or serum phase, producing an erythrocyte-depleted serum or plasma; and collecting the erythrocyte-depleted serum or plasma. A method of producing an ophthalmic solution (“eye drops”) meant for lubricating the eye of a subject comprises the steps of drawing a blood sample from a subject; adding erythrocyte sedimentation-accelerating agent(s) and an anticoagulant to the blood sample; placing the mixture in a vessel with an inclined well and allowing the phase separation of the solution into an erythrocyte phase and a plasma or serum phase, producing an erythrocyte-depleted serum or plasma; collecting the erythrocyte-depleted serum or plasma; treating the plasma with a platelet activating substance or agent; and applying the erythrocyte-depleted serum or plasma to the eye of the subject. A kit provides components, diagrams, compositions and instructions for performing the methods.

A transdermal patch for delivering lidocaine for pain relief comprises a backing layer, an adhesive layer, and a composition containing lidocaine in an amount ranging from about 1% to about 10% by weight and heparin as a non-anticoagulant permeation enhancer in an amount ranging from about 1% to about 50% by weight. The heparin enhances permeation of lidocaine through the skin without exerting systemic anticoagulant effects by temporarily disrupting lipid bilayers in the stratum corneum to create microchannels for increased diffusion of lidocaine molecules. The patch provides effective relief for multiple pain types including neuropathic pain, inflammatory pain, ischemic pain, post-surgical pain, nociplastic pain, mechanical pain, and compressive pain. The transdermal patch is configured to provide sustained release of lidocaine for periods ranging from about 8 hours to about 24 hours, reducing pain by at least 50% with minimal systemic absorption.

Current approaches in small diameter vascular grafts for coronary artery bypass surgeries fail to address physiological variations along the graft that contribute to thrombus formation and ultimately graft failure. An interlayer drug delivery system can sustain delivery of heparin through the graft with a high degree of temporal and spatial control. A heparin-loaded gelatin methacrylate interlayer sits between a biohybrid composed of decellularized bovine pericardium and poly(propylene fumarate) and UV crosslinking is controlled via 3D printed shadow masks. The masks enable control of the resultant gelMA crosslinking and properties by modulating the incident light intensity on the graft. High doses of heparin have detrimental effects on endothelial cell function. When exposed to heparin in a slower, more sustained manner consistent with the masks, endothelial cells behave similarly to untreated cells. Slower release profiles cause significantly more release of tissue factor pathway inhibitor, an anticoagulant, than a faster release profile.

The present invention discloses a hollow fiber membrane with excellent biocompatibility. The components of the hollow fiber membrane include a polysulfone / polyethersulfone matrix component and a grafted aromatic hydrophobic polymer containing 30% to 100% by weight of the matrix component. The preparation method of the grafted aromatic hydrophobic polymer comprises the following steps: dissolving an aromatic diamine in an organic solvent, then adding an aromatic dianhydride, and conducting a polymerization reaction for 4 to 10 hours. Then, adding a polyamine and stirring and dissolving the mixture to conduct a secondary reaction for 2 to 4 hours. Finally, adding a carboxyl-containing anticoagulant and conducting a grafting reaction for 12 to 48 hours to obtain the grafted aromatic hydrophobic polymer. The hollow fiber membrane of the present invention has stable performance, can effectively reduce the deposition of prothrombin and fibrin, etc., significantly improves the anticoagulant effect, and greatly enhances biocompatibility.

This invention is in the field of medical treatment, in particular the invention provides a method for the prevention and treatment for sepsis or septic shock. In particular the invention provides dosages and formulation for low anticoagulant heparin in the treatment of sepsis or septic shock. The invention further provides compositions for use in reducing C-reactive protein (CRP) levels in a patient, for example in the treatment, prevention or amelioration of disease where CRP plays a role, such as sepsis.

The application discloses a kind of automatic penetration sampling machines for nursing in nephrology department, and relates to the technical field of sampling device.It includes base, the upper surface of base is slidably connected with fixing frame, a plurality of groups of placing grooves are formed in the upper surface of fixing frame, and test tubes are arranged on the inner wall of placing groove, a plurality of groups of positioning cylinders are movably arranged on the upper surface of fixing frame, a transmission assembly for moving fixing frame is arranged in the base, a lifting assembly is arranged at the right position on the upper surface of base, and the lifting assembly includes motor.The application realizes automatic mixing operation of sample and anticoagulant in test tube by mixing assembly, without manual operation, which reduces the insufficient mixing of sample caused by insufficient number of test tube inversion or insufficient inversion angle to a certain extent, and the test tube generates synchronous rotation during inversion, which greatly increases the contact area of sample and anticoagulant, improves the mixing effect, and improves the accuracy of subsequent detection results to a certain extent.

The invention relates to the technical field of adiponectin detection kits, and discloses an immunoturbidimetric kit for detecting ADP, wherein the kit comprises an R1 reagent and an R2 reagent; the R1 reagent comprises: a buffer solution, 10-100 mmol / L; NaCl, 0.1-1 mol / L; an anticoagulant, 10-100 mmol / L; an aggregation promoter, 0.1-1%; a surfactant, 0.1-1 g / L; a preservative, 0.5-1 g / L; and a blocking agent, 0.05-0.2 mg / mL; wherein the anticoagulant in the R1 reagent is EDTA-Na 2 , sodium heparin, sodium citrate or a combination thereof; R2 reagent: buffer and antibody-coated latex microspheres, the preparation process of which requires cross-linking liquid, blocking liquid and preservation liquid; the kit prepared by the present invention achieves the beneficial technical effects of reducing the difference in serum and plasma measurement values, reducing batch differences and improving stability.

The utility model provides a disposable blood sampling device and peripheral blood sampling equipment, which relate to the technical field of medical devices, and include a blood sampling body, a quantitative blood sampling tube, an anticoagulant layer and a blocking layer; the internal volume of the quantitative blood sampling tube is quantified to ensure quantitative sampling of the sampled blood sample amount, so as to be able to test the quantitative product kit; the anticoagulant layer is used to limit the coagulation of the blood sample in the quantitative blood sampling tube, and the blocking layer is used by the blood sampling body to limit the internal pressure in the quantitative blood sampling tube; the anticoagulant can be used to ensure that the blood entering the quantitative blood sampling tube can be stored for a period of time, and at the same time the blocking layer can ensure the internal and external pressures of the quantitative blood sampling tube, and ensure the stability of the sampled blood in the quantitative blood sampling tube, thereby alleviating the technical problems existing in the prior art that the peripheral blood sampling operation is long and relatively scattered, the operation efficiency is low, and the patient experience is poor.

To provide a method and a system for achieving a consistent plasma anticoagulant ratio for a plasma product in plasma exchange processing.SOLUTION: There is provided a method for executing plasma exchange using a plasma separation system including a fluid flow circuit, a plasma separator, and a control unit. The method includes inputting a hematocrit value of a donor, setting a desired plasma anticoagulant ratio for a plasma product, calculating an initial ratio of an anticoagulant to whole blood (ACR), and executing separation by the separation system. The system also includes a programmable control unit having a screen for receiving an input from an operator, which is configured to give the initial ACR on the basis of the input from the operator, and activate the system on the basis of the initial ACR.SELECTED DRAWING: Figure 1

The utility model provides a low-molecular heparin calcium injector, which relates to the technical field of anticoagulant injection, and comprises an injector, an injection needle, a connecting rod, a connecting rod, a connecting rod and a connecting rod, and is characterized in that the injector is used for bearing medicament and outputting liquid medicine; the auxiliary part comprises a descending rod and an ascending rod; a linkage structure is arranged between the descending rod and the ascending rod, the descending rod and the ascending rod move reversely through the linkage structure, after the bottom end of the ascending rod points to the corresponding scale of the injector, the top end of the descending rod also descends by the corresponding height, and therefore when the push rod is pushed to descend, the push rod can be blocked by the descending rod, and the displacement distance of the push rod is limited. The problems that low-molecular-weight heparin calcium injection is subcutaneous injection, operation is troublesome, meanwhile, due to the influences of the environment, a light source and the like, metering scales on the surface of an injector can not be seen clearly, and the injection dosage of medical staff is not accurate easily are solved.

A heparin-like ternary copolymer containing zwitterionic, sulfonic, and carboxyl side chains is prepared by atom transfer radical polymerization (ATRP) from a first monomer containing a sulfonic acid group and an olefinic group, a second monomer containing an oxygen-carbon chain-linked zwitterionic group and an olefinic group, and a third monomer containing an oxygen-carbon chain-linked carboxyl side chain and an olefinic group. This ternary copolymer has a heparin-like structure and utilizes zwitterionic groups that mimic the hydrophilicity of cell membrane lecithin and negatively charged sulfonic acid groups with anticoagulant activity to inhibit both intrinsically and exogenously induced coagulation reactions. Anticoagulant coatings prepared from this copolymer can largely address the problem of zwitterionic polymers alone having poor anticoagulant properties and being unable to meet the anticoagulant requirements of biomedical devices. It also provides an effective solution to the multiple side effects and adverse reactions that systemic anticoagulants are prone to.